Total commercial support of CME scarcely budged in 2007, rising 1% to $1.2 billion, while the share of commercial support going to publishing and education companies declined 4.2% to $594 million, according to the ACCME’s annual report.
With its acquisition of Sciele Pharma, Osaka, Japan-based Shionogi & Co. will gain immediate entry into the US pharmaceutical market and inherit 720 seasoned sales reps.
Two diabetes product sites, Merck’s Januvia and Takeda’s Actos, came in first and second, respectively, in a new study measuring physicians’ web habits.
After nearly 20 years at Hoffmann-La Roche, William A. Garland, PhD, left big pharma in 1994 to direct research and development for a number of early-stage biotechs, including Lpath and Tosk.
With the lowest first-half spend since 2003, the top journals are left wondering if their luck will ever turn around. Eugene M. May reports on the few bright spots in the medical/surgical sector
It’s an Alice in Wonderland election for the industry, which finds itself favoring the Democratic candidate after eight years of alignment with the party of business. Matthew Arnold looks at the candidates
Utilizing an effective marketing strategy can go a long way in maximizing the lifetime value of a pharmaceutical brand. Harte-Hanks’ Julian Parreno looks at how Shire Pharmaceuticals overcame myriad competitive and regulatory obstacles to market its latest ADHD treatment, Adderall XR